Premas Biotech and Oravax to test their vaccine candidate against Omicron
Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
The offline store launch will complement the E-commerce website in building a rich consumer shopping experience
Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
ALASTIN’s patented, differentiated technology and products are highly synergistic with Galderma’s premium portfolio
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
The funds will be used to scale up existing operations and launch new products
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
Subscribe To Our Newsletter & Stay Updated